EuroBiotech: More Articles of Note


> Argenx struck a deal to use Halozyme’s delivery technology to develop subcutaneous formulations of its current and future drug candidates. The biotech paid $30 million (€26 million) upfront to land the deal. Statement 

> Newron Pharmaceuticals completed enrollment in its pivotal Rett syndrome trial. The milestone sets Newron up to deliver top-line results before the end of the year. Release 

> Sotio named Harald Fricke as its CMO. Fricke last worked at Apogenix, a company he co-founded in 2006. Statement 

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

> Audion Therapeutics posted phase 1 data on its notch inhibitor in patients with mild to moderate sensorineural hearing loss. A phase 2 trial of the drug started last month. Release  

> BioLineRx priced $15.4 million worth of shares and warrants. Statement

> UniQure dosed the first patient in its pivotal hemophilia B trial. The gene therapy trial is expected to be fully enrolled by the end of the year. Release 

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.